Pfizer has opened a new, $214 million biotech manufacturing facility in Sweden. The 68,000-square-foot plant will make recombinant proteins based on e. coli and yeast as well as a branded human growth hormone. But Pfizer says that it built the plant to accommodate the production of a variety of therapies. Report [1]
Links:
[1] http://www.in-pharmatechnologist.com/On-your-radar/Lifecycle-management/Pfizer-inaugurates-new-214m-Swedish-biotech-plant